11:25 PM EDT, 08/16/2026 (MT Newswires) -- Sandoz Group (SDZ.SW) said Monday it entered into a $322 million collaboration agreement with biopharmaceutical company Shanghai Henlius Biotech concerning up to 10 biosimilars. The Swiss drugmaker gains global commercialization rights outside China for the covered biosimilars, agreeing to pay milestone-based considerations, with near-term payments of up to $100.5 million for the initial assets. Henlius will be in charge of development and manufacturing. Initial assets covered in the deal include a proposed biosimilar for cetuximab, evolocumab and belimumab, as well as an option for recombinant human hyaluronidase. Sandoz's biosimilar pipeline increased to 39 assets following the deal, with potential further expansion to up to 46 assets.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.